Summary of Clover Health Investments (CLOV) FY Conference - August 12, 2025 Company Overview - Clover Health is a tech-enabled insurance company focused on Medicare Advantage, experiencing growth despite industry challenges [3][6] - The company aims to deliver excellent clinical outcomes while providing broad access to healthcare for its members [3][6] Key Industry Insights - The Medicare Advantage market is substantial, valued at approximately $500 billion annually, with around 35 million enrollees in the U.S. [6] - Clover Health's unique approach includes a high percentage of members (97%) enrolled in PPO plans, allowing for wider access [7] Financial Performance - Membership is projected to grow by 32% in 2025, with revenue growth expected at 37% [7] - The company has maintained adjusted EBITDA profitability year-over-year, with flat profitability compared to the first half of the previous year [7][19] - Positive cash flow from operating activities was reported at approximately $84 million in 2024 [18] Technology and Clinical Outcomes - Clover Assistant, powered by machine learning and AI, enables physicians to diagnose and treat diseases earlier, leading to better health outcomes and lower total care costs [6][10] - Physicians using Clover Assistant can identify and treat chronic diseases significantly earlier, with diabetes treatment starting on average 36 months earlier [12] - The company boasts a high HEDIS score of 4.94 out of 5, indicating strong clinical quality [14] Business Model Differentiation - Clover Health's model emphasizes a clinical approach at the point of care, contrasting with traditional players that focus on back-office operations [15][16] - The company does not engage in traditional risk delegation, which is common among competitors [16] Growth Strategy - Clover Health is focused on expanding its presence in core markets: New Jersey, Georgia, South Carolina, and Texas, where it holds a 12% market share in New Jersey [20][21] - The company is also exploring opportunities to offer its technology to third-party providers and payers, enhancing its revenue model [22] Future Outlook - Membership and revenue growth are expected to accelerate, with a potential increase in profitability for 2026 [23] - The transition from a three-and-a-half-star to a four-star payment year is anticipated to add around 5% in premium fees [41] - The company is preparing for the upcoming Annual Enrollment Period (AEP) with a strategy focused on precise growth [33] Additional Considerations - Clover Health is investing in R&D and quality improvements while managing costs through efficiency programs [19] - The company is addressing higher utilization trends in Part D and expects a 40% increase in direct subsidies from CMS next year [28] This summary encapsulates the key points discussed during the conference, highlighting Clover Health's unique position in the Medicare Advantage market, its technological advancements, and its growth strategies moving forward.

Financial Data and Key Metrics Changes - The company reported a 32% year-over-year growth in Medicare Advantage membership, reaching over 106,000 members [20] - Insurance revenue increased by 34% to $470 million in Q2 2025, with year-to-date revenue at $927 million [20] - Adjusted EBITDA for Q2 2025 was $70 million, maintaining year-to-date adjusted EBITDA at $43 million [24] - GAAP net loss improved by $4 million year-to-date to $12 million [19][24] - The insurance benefit expense ratio (BER) was reported at 88.4%, up from 76.1% in 2024 [24] Business Line Data and Key Metrics Changes - The Medicare Advantage segment continues to show robust growth, with a focus on leveraging technology to enhance care management [5][8] - The company is experiencing elevated utilization levels in supplemental benefits and Part D, which are being monitored closely [21][22] Market Data and Key Metrics Changes - The company is insulated from broader industry pressures affecting Medicaid and ACA markets due to its focus on Medicare Advantage [10] - The Part D direct subsidy rate for 2026 is significantly higher than for 2025, indicating potential cost pressures that may alleviate in 2026 [12] Company Strategy and Development Direction - The company aims to achieve profitability, return to growth while sustaining profitability, and leverage its differentiated model for accelerated growth [6] - The focus remains on expanding the reach of Clover Assistant and enhancing member retention in existing markets [14] - The company is strategically positioned for a four-star payment year in 2026, which is expected to provide financial tailwinds [32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming membership growth season, potentially stronger than the current year [7] - The company is closely monitoring the impacts of the Part D IRA changes and anticipates variability in performance modeling [11] - Management believes that the technology-centric care delivery model will differentiate the company amidst industry pressures [12][13] Other Important Information - The company has maintained a strong cash position with $389 million in cash and investments as of Q2 2025 [26] - Days in claims payable decreased to 32 days, indicating normalization of claims inventory [25] Q&A Session Summary Question: How much conservatism is embedded in the raised guidance on the BER? - The increase in the BER guidance is primarily related to Part D and supplemental benefits, with initiatives in place to monitor these trends going forward [36][37] Question: When did the pressures start emerging, and how much was captured in the bids for next year? - The pressures, especially on Part D, have been tracked throughout the year, with adjustments made in pricing for bids [38][39] Question: What are the drivers for improvements in adjusted SG&A? - Improvements are mainly due to cost efficiencies and renegotiations with partners, reflecting the company's strong growth [41][42] Question: What response has been received from the COPD white paper? - The company plans to continue producing similar papers to highlight the benefits of using Clover Assistant in managing care [43][44] Question: Is the elevated cost trend localized or broad-based? - The elevated cost trends are not specific to new or returning members and are being monitored across the board [48][50] Question: How is the competitive landscape changing for the upcoming AEP? - Competitors are pulling back in certain areas, particularly within PPO networks, which may benefit the company due to its strong positioning [51][52]

Second Quarter 2025 Earnings Conference Call August 5, 2025 LGTMs: Date: Andrew T. (Input) Verbal LGTM 8/1 Peter K. LGTM 8/1 af Legal (Karen / Peter R.) LGTM 8/4 Accounting (#s confirm) LGTM (7/31 - Joe) Disclaimer This presentation and the accompanying oral presentation include forward-looking statements, including, without limitation, statements regarding future events and Clover Health Investments, Corp.'s ("Clover Health," "we," "our," or "us") expectations regarding Adjusted EBITDA, Adjusted Net income ...

Core Insights - Clover Health Investments, Corp. reported strong financial results for Q2 2025, highlighting significant membership and revenue growth, along with sustained profitability metrics [2][3][4] - The company's technology-first model is credited for driving better care management and improved health outcomes for members, particularly in Medicare Advantage plans [3][20] - Clover Health updated its full-year 2025 guidance, maintaining insurance revenue expectations while improving projections for adjusted SG&A and membership growth [10][4] Financial Performance - Q2 2025 insurance revenue reached $469.8 million, a 34.3% increase from $349.9 million in Q2 2024 [4][3] - Total revenues for Q2 2025 were $477.6 million, up 34% year-over-year [4][3] - Average Medicare Advantage membership increased by 31.8% year-over-year to 105,494 [4][3] - Adjusted net income from continuing operations was $16.7 million, down 53.5% from $35.9 million in Q2 2024 [4][3] - Adjusted EBITDA for Q2 2025 was $17.1 million, a decrease of 52.8% compared to $36.2 million in Q2 2024 [4][3] Membership and Revenue Guidance - The company expects average Medicare Advantage membership to be between 104,000 and 108,000 for the full year 2025, representing a 32% growth year-over-year at the midpoint [4][10] - Insurance revenue guidance for 2025 is maintained at $1.800 billion to $1.875 billion, indicating a 37% growth year-over-year at the midpoint [10][4] - Adjusted SG&A is projected to be between $335 million and $345 million, improving as a percentage of total revenues to 18% - 19% [10][4] Operational Metrics - The Insurance Benefits Expense Ratio (BER) for Q2 2025 was 88.4%, up from 76.1% in Q2 2024 [4][3] - The company reported a net loss from continuing operations of $10.6 million for Q2 2025, compared to a net income of $7.2 million in Q2 2024 [4][3] - Total cash, cash equivalents, and investments decreased by 19.4% to $389.3 million from $482.8 million year-over-year [4][3]

Core Insights - Clover Health Investments (CLOV) is expected to report second-quarter 2025 results on August 5, with earnings estimated at 3 cents per share and revenues at $482.5 million, reflecting a year-over-year growth of 200% and 35.4% respectively [1][5] - The consensus for 2025 revenues stands at $1.89 billion, indicating a 37.7% increase year-over-year, while the EPS estimate is 11 cents, suggesting a decline of 21.4% year-over-year [2] Financial Performance - Clover Health has consistently surpassed earnings estimates in the past four quarters, achieving an average surprise of 114.58% [2] - The company has a Zacks Rank of 3 (Hold), with an Earnings ESP of 0.00%, indicating no expected earnings surprise for the upcoming quarter [3][4] Growth Factors - The company reported a 30% growth in Medicare Advantage (MA) membership and a 279% increase in adjusted earnings year-over-year for the first quarter [5] - The Clover Assistant has demonstrated an 18% reduction in hospitalizations and 25% lower 30-day readmissions for congestive heart failure patients, contributing to cost efficiencies [6][7] Market Position - Member growth remains strong, particularly in key markets like New Jersey, supported by effective cohort management strategies [8] - Clover Health's Counterpart Health is expanding its technology reach, although the financial impact from non-insurance revenue in Q2 is expected to be limited [9] Valuation and Performance - Year-to-date, CLOV shares have declined by 8.2%, underperforming peers such as Alignment Healthcare and Oscar Health [10] - Clover Health trades at a forward 12-month price-to-sales ratio of 0.65, reflecting stronger growth expectations compared to its peers [11] Strategic Outlook - The company is focused on improving clinical outcomes and expanding its technology capabilities, with a cautious outlook on profitability and revenue contributions from Counterpart Health [15] - Investors are advised to monitor updates on utilization trends and the sustainability of operating leverage before making new investments [15]

Company Overview - Clover Health Investments, Corp. is a physician enablement technology company focused on providing access to quality healthcare for Medicare recipients, particularly seniors who have historically faced challenges in accessing affordable healthcare [2] - The company utilizes its software platform, Clover Assistant, to aggregate patient data across the healthcare ecosystem, enhancing clinical decision-making and improving health outcomes through early identification and management of chronic diseases [2] Business Strategy - Clover Health offers PPO and HMO Medicare Advantage plans across several states, with a particular emphasis on its flagship wide-network, high-choice PPO plans [2] - The company extends its data-driven technology platform to healthcare providers outside its Medicare Advantage plan through its subsidiary, Counterpart Health, aiming to improve patient outcomes and reduce healthcare costs on a national scale [2] Recent Developments - The Chief Financial Officer of Clover Health, Peter Kuipers, is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, at 11:00 a.m. Eastern Time [1]

Core Insights - Clover Health Investments, Corp. has appointed Joseph Oldakowski as Vice President of Finance and Controller, who will oversee corporate accounting and financial reporting [1][4] - Oldakowski brings nearly 20 years of experience in finance and accounting, having previously served at Point32Health and EmblemHealth [2][3] - Clover Health focuses on providing accessible healthcare to Medicare recipients, utilizing its software platform, Clover Assistant, to improve health outcomes [5] Company Overview - Clover Health is a physician enablement technology company dedicated to enhancing healthcare access for Medicare beneficiaries, particularly seniors [5] - The company offers PPO and HMO Medicare Advantage plans across several states, emphasizing a wide-network, high-choice PPO plan [5] - Clover Assistant aggregates patient data to support clinical decision-making and manage chronic diseases, demonstrating positive impacts on medication adherence and chronic conditions [5] Leadership Insights - CFO Peter Kuipers highlighted Oldakowski's expertise in finance transformations and integrity as key attributes for Clover's growth [4] - Oldakowski expressed enthusiasm for joining Clover Health, emphasizing the importance of accessible and high-quality healthcare [4]

Core Viewpoint - Clover Health Investments, Corp. has launched a community-based pharmacy pilot program in New Jersey aimed at improving medication management for seniors and enhancing their health outcomes through local pharmacies [1][2][3] Group 1: Program Details - The pilot program is in partnership with IPC Digital Health and utilizes the iCare+ Independent Pharmacy Network, which includes thousands of community pharmacies [2] - Local pharmacies will implement innovative care tools and virtual services to assist Clover members with chronic conditions in adhering to their medication regimens and reducing hospital visits [2][3] - The program aims to leverage real-time tools powered by Clover Assistant data and AI models to monitor prescription fills and collaborate with local healthcare providers [3] Group 2: Strategic Importance - The initiative represents a new model for supporting Clover Health's members in New Jersey, focusing on community engagement and personalized care [3][4] - Clover Health emphasizes the importance of local relationships and technology in delivering healthcare that feels personal, aligning with its broader commitment to investing in New Jersey communities [4] - The partnership with IPC Digital Health is seen as a way to empower independent pharmacies to provide smarter, more connected care [4] Group 3: Company Overview - Clover Health is a physician enablement technology company focused on providing access to affordable, high-quality healthcare for Medicare beneficiaries, particularly seniors [5] - The company utilizes its Clover Assistant software platform to aggregate patient data and support clinical decision-making, aiming to improve health outcomes through early identification and management of chronic diseases [5] - Clover Health offers PPO and HMO Medicare Advantage plans and extends its data-driven technology benefits to a wider audience through its subsidiary, Counterpart Health [5]

Company Overview - Clover Health Investments, Corp. is a physician enablement technology company focused on providing access to quality healthcare for Medicare beneficiaries, particularly seniors who have historically faced challenges in accessing affordable healthcare [2] - The company utilizes its software platform, Clover Assistant, to aggregate patient data and support clinical decision-making, aiming to improve health outcomes through early identification and management of chronic diseases [2] - Clover Health offers PPO and HMO Medicare Advantage plans across several states, with a particular emphasis on its wide-network, high-choice PPO plans [2] Upcoming Financial Results - Clover Health will release its financial results for the second quarter of 2025 after market close on August 5, 2025 [1] - A conference call and webcast will be held at 5:00 p.m. Eastern Time on the same day to discuss the company's business and financial performance [1][3] - Investors can access the conference call via telephone or through a live and archived webcast available on the company's Investor Relations website [3]

Company Overview - Clover Health Investments, Corp. is a physician enablement technology company focused on providing access to quality healthcare for Medicare recipients, particularly seniors who have historically faced challenges in accessing affordable healthcare [5] - The company utilizes its software platform, Clover Assistant, to aggregate patient data and support clinical decision-making, aiming to improve health outcomes through early identification and management of chronic diseases [5] Recent Developments - Clover Health announced its inclusion in the Russell 3000® Index, effective June 30, 2025, as part of the annual reconstitution of the Russell indexes [1][2] - This inclusion is expected to enhance the company's visibility within the investment community and is seen as a significant achievement in broadening awareness and engagement [3] Market Context - The Russell 3000® Index includes the 4,000 largest US stocks ranked by total market capitalization as of April 30, 2025, and membership lasts for one year [2] - Membership in the Russell 3000® Index also grants automatic inclusion in either the large-cap Russell 1000® Index or the small-cap Russell 2000® Index, along with relevant growth and value style indexes [2] Industry Impact - The Russell indexes are widely utilized by investment managers and institutional investors, with approximately $10.6 trillion in assets benchmarked against them as of June 2024 [3] - FTSE Russell, the provider of these indexes, is recognized for its objective market capitalization and style attributes in determining membership [2][3]